Immunomedics has announced that results from their Phase II study of epratuzumab in systemic lupus erythematosus (SLE) have been published in the online edition of Arthritis Research & Therapy.

Fourteen patients with moderately active SLE were enrolled in this open- label, single-center study. At the beginning of the study, total baseline BILAG (British Isles Lupus Assessment Group) scores for the group ranged from 6 to 12. In all 14 patients at some point during the study, total BILAG scores decreased by 50 percent or more. Almost all patients (93 percent) experienced improvement in at least one BILAG B- or C-level disease activity at six, 10, and 18 weeks. Additionally, three patients with multiple BILAG B involvement at baseline had completely resolved all B-level disease activities by 18 weeks.